Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated April 8, 2025, reports a transaction in own shares for the month of April 2025. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS).
Key Financial Metrics and Transaction Details
The filing details a share buyback transaction executed under a programme announced on March 28, 2025. The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures.
| Metric | Value |
|---|---|
| Date of Purchase | April 7, 2025 |
| Shares Purchased | 845,272 |
| Highest Price Paid | 372.40 pence |
| Lowest Price Paid | 357.70 pence |
| Volume Weighted Average Price | 363.98 pence |
| Registered Share Capital | 9,033,999,998 ordinary shares |
| Treasury Shares Held | 4,080,205 |
| Voting Shares Outstanding | 9,029,919,793 |
Material Changes
Following the settlement of the buyback, the number of ordinary shares with voting rights decreased to 9,029,919,793. This figure is material for shareholders determining notification requirements under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It strictly reports the execution of the share repurchase and provides a link to the full trade breakdown under the Market Abuse Regulation.
Investor Verification Checklist
- Verify the updated voting share count of 9,029,919,793 for disclosure threshold calculations.
- Confirm the total volume of shares repurchased under the March 28, 2025 programme to date.
- Review the full trade breakdown available via the provided London Stock Exchange link for granular pricing data.
- Note that this filing does not contain operational or financial performance metrics.